Literature DB >> 8651969

Childhood-onset scleroderma: is it different from adult-onset disease.

R Vancheeswaran1, C M Black, J David, N Hasson, J Harper, D Atherton, P Trivedi, P Woo.   

Abstract

OBJECTIVE: To distinguish childhood-onset scleroderma from adult-onset disease.
METHODS: The clinical and serologic features of 58 patients with childhood-onset scleroderma (11 patients with diffuse cutaneous systemic sclerosis [SSc], 16 with linear SSc, 14 with linear morphea, and 17 with morphea) were examined in the largest cohort of such patients studied to date. These parameters were compared with data obtained from patients with adult-onset disease.
RESULTS: Childhood-onset scleroderma resembled adult-onset disease with regard to the heterogeneity of clinical expression and subsets of disease, but it also differed from adult-onset disease in a number of clinical and laboratory parameters. The predominant childhood-onset disease presentation was the localized form of the disease, with limited and diffuse SSc being less notable. There was a significant association of trauma with childhood-onset scleroderma (P < 0.0001), which was not noted in adult-onset disease. Furthermore, in contrast to adult disease, patients with childhood-onset disease had normal levels of parameters of vascular activation (von Willebrand factor, angiotensin-converting enzyme, E-selectin, and endothelin-1), T cell activation (soluble interleukin-2 receptors), and collagen synthesis (carboxy-terminal type I and amino-terminal type III), a notable lack of anticentromere antibodies, and abnormal coagulation indices.
CONCLUSION: A number of features distinguish childhood-onset scleroderma from adult-onset disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651969     DOI: 10.1002/art.1780390624

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

Review 1.  Systemic manifestations in localized scleroderma.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

2.  Morphea developing at the site of healed herpes zoster.

Authors:  Tae Woo Noh; Sang Hoon Park; Yoo Seok Kang; Un Ha Lee; Hyun Su Park; Sang Jai Jang
Journal:  Ann Dermatol       Date:  2011-05-27       Impact factor: 1.444

3.  Zosteriform Morphea Without History of Herpes Zoster Infection.

Authors:  Hatice Ataş; Müzeyyen Gönül; Mehmet Koçak; Aysun Gökçe
Journal:  Arch Rheumatol       Date:  2016-08-01       Impact factor: 1.472

4.  Juvenile systemic sclerosis: experience from a tertiary care center from India.

Authors:  Narendra Kumar Bagri; Dinesh Raj; Jasmeet Kaur; Harish Punia; Isha Saini; Rakesh Lodha; S K Kabra
Journal:  Rheumatol Int       Date:  2017-08-22       Impact factor: 2.631

Review 5.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 7.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

8.  Parry-Romberg Syndrome Associated with Localized Scleroderma.

Authors:  Jelena Maletic; Vassiliki Tsirka; Panos Ioannides; Dimitrios Karacostas; Nikolaos Taskos
Journal:  Case Rep Neurol       Date:  2010-06-01

Review 9.  Overview of Juvenile localized scleroderma and its management.

Authors:  Suzanne C Li; Rong-Jun Zheng
Journal:  World J Pediatr       Date:  2019-11-30       Impact factor: 2.764

10.  Disabling pansclerotic morphea of childhood with extracutaneous manifestations.

Authors:  Mahendra M Kura; Saurabh R Jindal
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.